Latest News

Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study) Condition: Testicular Cancer Purpose: Depending on disease stage, testicular cancer (TC) treatment consists of an orchidectomy, alone or followed by radiotherapy (RT) or platinum-based chemotherapy (CT). TC survival rates are above 90% nowadays, which results in growing TC survivor population. Because […]

Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (>=75), “Vulnerable” or “Frail” , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG) Condition: Prostate Cancer Intervention: Drug: Docetaxel every 3 weeks + […]

A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone Condition: Prostate Cancer Metastatic to Bone Intervention: Drug: Radium Ra 223 Dichloride Radiation: Radiation Purpose: This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve men with oligometastatic prostate cancer to the bone. […]

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Condition: Squamous Cell Carcinoma of the Penis, Usual Type Intervention: Procedure: ILND – Inguinal Lymph Node Dissection Drug: Paclitaxel Drug: Ifosfamide Drug: Cisplatin Radiation: Intensity modulated radiation treatment (IMRT) Procedure: Prophylactic PLND – pelvic lymph node dissection Purpose: This is an international phase III trial, […]

A Phase I/IB Study of Avelumab in Combination With Gemcitabine for Advanced Renal Cell Carcinoma With Sarcomatoid Differentiation Condition: Metastatic sRCC Intervention: Drug: Avelumab Drug: Gemcitabine Purpose: To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC. Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03483883 Sponsor: Abramson […]

A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients Condition: Stage IV Renal Cell Cancer AJCC V7 Intervention: Drug: Pembrolizumab Radiation: Stereotactic Body Radiation Therapy Purpose: This study is designed as a phase-II proof of […]

To evaluate the impact of frailty on adverse perioperative outcomes in patients treated with radical cystectomy for bladder cancer. We identified 9,459 adults (age ≥18) in the Nationwide Readmission Database (NRD) who underwent radical cystectomy in 2014 for bladder cancer. We defined patients’ frailty status using Johns Hopkins Adjusted Clinical Groups frailty-defining diagnosis indicator and […]

To report long-term outcomes with dose-escalated, image-guided adaptive radiotherapy (ART) for bladder preservation in muscle-invasive bladder cancer (MIBC). All MIBC patients receiving bladder-preserving ART at our institute from 2009 to 2018 were analysed. For ART, three anisotropic planning target volumes (PTV) were concentrically grown around the simulation bladder volume. A library of intensity-modulated radiotherapy plans […]

Objective: Chemotherapy is a major therapeutic method for bladder urothelial carcinoma (BUC), which can effectively improve the prognosis of BUC patients, but the chemoresistance often leads to chemotherapy failure. This study will research the regulatory roles and molecular mechanism of miR-101-3p in BUC chemoresistance. Materials and Methods: The quantitative real-time PCR was used to detect […]

OBJECTIVE. The objective of our study was to analyze the feasibility and potential role of robotic-assisted transrectal MRI-guided biopsy for the diagnosis of prostate cancer. MATERIALS AND METHODS. A total of 57 patients (mean age, 67 ± 6 [SD] years; age range, 57-83 years; mean prostate-specific antigen level, 10.7 ± 6.1 ng/mL) with a single […]